Equities researchers at StockNews.com began coverage on shares of Surmodics (NASDAQ:SRDX – Get Free Report) in a research note issued on Thursday. The brokerage set a “hold” rating on the stock.
Separately, Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research report on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $50.00.
Read Our Latest Stock Analysis on SRDX
Surmodics Price Performance
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its position in shares of Surmodics by 7.5% in the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company’s stock valued at $202,000 after purchasing an additional 481 shares during the last quarter. SG Americas Securities LLC increased its holdings in Surmodics by 14.7% in the first quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock valued at $151,000 after buying an additional 660 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after buying an additional 673 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Surmodics by 3.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 36,425 shares of the company’s stock worth $1,531,000 after acquiring an additional 1,221 shares in the last quarter. Finally, Wolverine Asset Management LLC increased its holdings in shares of Surmodics by 6.9% in the 3rd quarter. Wolverine Asset Management LLC now owns 27,766 shares of the company’s stock valued at $1,077,000 after acquiring an additional 1,800 shares during the last quarter. 96.63% of the stock is owned by institutional investors and hedge funds.
About Surmodics
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
- Five stocks we like better than Surmodics
- What is the Euro STOXX 50 Index?
- What a Trump Win Looks Like for the Market Now and Into 2025
- Earnings Per Share Calculator: How to Calculate EPS
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- 3 REITs to Buy and Hold for the Long Term
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.